Wealth Enhancement Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$352K	Sell	12,678 -2,674	-17%	-$62.3K	﹤0.01%	3047
2026 Q1	$363K	Sell	15,352 -1,080	-7%	-$27.6K	﹤0.01%	2600
2025 Q4	$480K	Buy	16,432 +2,221	+16%	+$56.9K	﹤0.01%	2510
2025 Q3	$292K	Sell	14,211 -1,455	-9%	-$22.9K	﹤0.01%	2822
2025 Q2	$217K	Buy	+15,666	New	+$220K	﹤0.01%	2920
2025 Q1	–	Sell	-20,912	Closed	-$291K	–	2987
2024 Q4	$291K	Buy	+20,912	New	+$229K	﹤0.01%	2409
2024 Q1	–	Sell	-20,000	Closed	-$64.6K	–	2488
2023 Q4	$64.6K	Buy	20,000 +10,000	+100%	+$27.2K	﹤0.01%	2200
2023 Q3	$53.1K	Buy	+10,000	New	+$85K	﹤0.01%	2158

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wealth Enhancement Advisory Services's ARQT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Arcutis Biotherapeutics (ARQT) stake by 17% in Q2 2026, selling an estimated $62.3K and leaving 12,678 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #3047.

Wealth Enhancement Advisory Services first reported a position in ARQT in Q3 2023 and has held it in 8 quarters since. The position peaked at $480K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Wealth Enhancement Advisory Services held 12,678 shares of Arcutis Biotherapeutics worth $352K as of Q2 2026.
Wealth Enhancement Advisory Services sold 2,674 Arcutis Biotherapeutics shares in Q2 2026, an estimated $62.3K.
Arcutis Biotherapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3047 holding.
Wealth Enhancement Advisory Services first reported a position in Arcutis Biotherapeutics in Q3 2023 and has held it in 8 quarters since.
Wealth Enhancement Advisory Services's Arcutis Biotherapeutics position peaked at $480K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.